

DAFTAR PUSTAKA

- Akanbi, O.E., Njom, H.A., Fri, J., Otigbu, A.C. and Clarke, A.M., 2017. Antimicrobial susceptibility of *Staphylococcus aureus* isolated from recreational waters and beach sand in eastern cape province of South Africa. *International Journal of Environmental Research and Public Health*, 14(9), p.1001.
- Andriole, V.T., 2000. *The Quinolones* 3rd ed. London: Academic Press.
- Asif, M., 2013. Rifampin and Their Analogs: A Development of Antitubercular Drugs. *World Journal of Organic Chemistry*, 1(2), pp.14-19.
- Böcher, S., Skov, R.L., Knudsen, M.A., Guardabassi, L., Mølbak, K., Schouenborg, P., Sørup, M. and Westh, H., 2010. The search and destroy strategy prevents spread and long-term carriage of methicillin-resistant *Staphylococcus aureus*: results from the follow-up screening of a large ST22 (E-MRSA 15) outbreak in Denmark. *Clinical Microbiology and Infection*, 16(9), pp.1427-1434.
- Bradley, S.F., 2007. Eradication or decolonization of methicillin-resistant *Staphylococcus aureus* carriage: what are we doing and why are we doing it?.
- Cai, X.C., Xi, H., Liang, L., Liu, J.D., Liu, C.H., Xue, Y.R. and Yu, X.Y., 2017. Rifampicin-resistance mutations in the *rpoB* Gene in *Bacillus velezensis* CC09 have pleiotropic effects. *Frontiers in microbiology*, 8, p.178.
- Custovic, A., Smajlovic, J., Hadzic, S., Ahmetagic, S., Tihic, N. and Hadzagic, H., 2014. Epidemiological surveillance of bacterial nosocomial infections in the surgical intensive care unit. *Materia Socio-Medica*, 26(1), p.7.

- David, M.Z. and Daum, R.S., 2017. Treatment of *Staphylococcus aureus* infections. In *Staphylococcus aureus* (pp. 325-383). Springer, Cham.
- de Haas, C.J., Veldkamp, K.E., Peschel, A., Weerkamp, F., Van Wamel, W.J., Heezius, E.C., Poppelier, M.J., Van Kessel, K.P. and Van Strijp, J.A., 2004. Chemotaxis inhibitory protein of *Staphylococcus aureus*, a bacterial antiinflammatory agent. *Journal of Experimental Medicine*, 199(5), pp.687-695.
- Epstein, R.J., 2002. *Human Molecular Biology: An Introduction to the Molecular basis of health and disease*. Cambridge University Press. pp.84.
- Festary, A., Kourí, V., Correa, C.B., Verdasquera, D., Roig, T. and Couret, M.P., 2015. Cytomegalovirus and herpes simplex infections in mothers and newborns in a Havana maternity hospital. *MEDICC review*, 17, pp.29-34.
- Foster T. 1996. *Staphylococcus*. In: Baron S, editor. *Medical Microbiology*. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; Chapter 12.
- Hameed, S., Moganeradj, K., Mahmood, N., McHugh, T.D., Chaudhry, M.N. and Arnold, C., 2017. Sequence analysis of the rifampicin resistance determining region (RRDR) of *rpoB* gene in multidrug resistance confirmed and newly diagnosed tuberculosis patients of Punjab, Pakistan. *PLoS one*, 12(8), p.e0183363.
- Kaasch, A.J., Barlow, G., Edgeworth, J.D., Fowler Jr, V.G., Hellmich, M., Hopkins, S., Kern, W.V., Llewelyn, M.J., Rieg, S., Rodriguez-Baño, J. and Scarborough, M., 2014. *Staphylococcus aureus* bloodstream infection: a

pooled analysis of five prospective, observational studies. *Journal of Infection*, 68(3), pp.242-251.

Khan, H.A., Baig, F.K. and Mehboob, R., 2017. Nosocomial infections: Epidemiology, prevention, control and surveillance. *Asian Pacific Journal of Tropical Biomedicine*, 7(5), pp.478-482.

Kim, C.J., Kim, H.B., Oh, M.D., Kim, Y., Kim, A., Oh, S.H., Song, K.H., Kim, E.S., Cho, Y.K., Choi, Y.H. and Park, J., 2014. The burden of nosocomial staphylococcus aureus blood stream infection in South Korea: a prospective hospital-based nationwide study. *BMC Infectious Diseases*, 14(1), p.590.

Ko, K.S., Lee, H.K., Park, M.Y., Lee, K.H., Yun, Y.J., Woo, S.Y., Miyamoto, H. and Kook, Y.H., 2002. Application of RNA polymerase β -subunit gene (rpoB) sequences for the molecular differentiation of Legionella species. *Journal of clinical microbiology*, 40(7), pp.2653-2658.

Kubica M, Guzik K, Koziel J, Zarebski M, Richter W, Gajkowska B, Golda A, Maciag-Gudowska A, Brix K, Shaw L, Foster T, Potempa J. 2008. A potential new pathway for *Staphylococcus aureus* dissemination: the silent survival of *S. aureus* phagocytosed by human monocyte-derived macrophages. *PLoS One*. 3: e1409

Laupland, K.B., Lyttikäinen, O., Sgaard, M., Kennedy, K.J., Knudsen, J.D., Ostergaard, C., Galbraith, J.C., Valiquette, L., Jacobsson, G., Collignon, P. and Schnheyder, H.C., 2013. The changing epidemiology of Staphylococcus aureus bloodstream infection: a multinational population-based surveillance study. *Clinical Microbiology and Infection*, 19(5), pp.465-471.

- Liu, G.Y., 2009. Molecular pathogenesis of *Staphylococcus aureus* infection. *Pediatric Research*, 65(5), p.71R.
- Lowy, F.D., 1998. *Staphylococcus aureus* infections. *New England journal of medicine*, 339(8), pp.520-532.
- Mbim, E.N., Mboto, C.I. and Agbo, B.E., 2016. A review of nosocomial infections in Sub-Saharan Africa. *British Microbiology Research Journal*, 15(1), pp.1-11.
- Mick, V., Domínguez, M.A., Tubau, F., Liñares, J., Pujol, M. and Martín, R., 2010. Molecular characterization of resistance to Rifampicin in an emerging hospital-associated Methicillin-resistant *Staphylococcus aureus* clone ST228, Spain. *BMC Microbiology*, 10(1), p.1.
- Moy, T.I., Daniel, A., Hardy, C., Jackson, A., Rehrauer, O., Hwang, Y.S., Zou, D., Nguyen, K., Silverman, J.A., Li, Q. and Murphy, C., 2011. Evaluating the activity of the RNA polymerase inhibitor myxopyronin B against *Staphylococcus aureus*. *FEMS microbiology letters*, 319(2), pp.176-179.
- Murray, R.K., Granner, D.K., Mayes, P.A., Rodwell, V.W., 2003. *Harper's illustrater Biochemistry*, Twenty Sixth edition. McGraw-Hill company. New York. Pp. 303-305.
- Rasigade, J.P. and Vandenesch, F., 2014. *Staphylococcus aureus*: a pathogen with still unresolved issues. *Infection, Genetics and Evolution*, 21, pp.510-514.
- Revelas, A., 2012. Healthcare-associated infections: A public health problem. *Nigerian Medical Journal: Journal of The Nigeria Medical Association*, 53(2), p.59.

- Rizka, MA., 2013. *Profil Mutasi Genetik gyrB pada isolat Klinik Acinetobacter baumannii yang Resisten Terhadap Siprofloksasin*. Surabaya: Universitas Airlangga
- Růžička, M., Kulhánek, P., Radová, L., Čechová, A., Špačková, N., Fajkusová, L. and Réblová, K., 2017. DNA mutation motifs in the genes associated with inherited diseases. *PLoS one*, 12(8), p.e0182377.
- Samuel, S.O., Kayode, O.O., Musa, O.I., Nwigwe, G.C., Aboderin, A.O., Salami, T.A.T. and Taiwo, S.S., 2010. Nosocomial infections and the challenges of control in developing countries. *African Journal of Clinical and Experimental Microbiology*, 11(2).
- Severinov, K., Mustaev, A., Kukarin, A., Muzzin, O., Bass, I., Darst, S.A. and Goldfarb, A., 1996. Structural Modules of the Large Subunits of RNA Polymerase Introducing Archaeobacterial and Chloroplast Split Sites in the β and β' Subunit of Escherichia coli RNA Polymerase. *Journal of Biological Chemistry*, 271(44), pp.27969-27974.
- Sweetman, 2009. *Martindale The Complete Drug Reference*, 36th Ed. London: Pharmaceutical Press.
- Taylor TA, Unakal CG. *Staphylococcus Aureus*. [Updated 2018 Oct 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
- Thwaites, G.E., Scarborough, M., Szubert, A., Nsutebu, E., Tilley, R., Greig, J., Wyllie, S.A., Wilson, P., Auckland, C., Cairns, J. and Ward, D., 2018. Adjunctive rifampicin for *Staphylococcus aureus* bacteraemia (ARREST): a

multicentre, randomised, double-blind, placebo-controlled trial. *The Lancet*, 391(10121), pp.668-678.

Tang, S.Y., Davis, J.S., Eichenberger, E., Holland, T.L. and Fowler, V.G., 2015. *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clinical Microbiology Reviews*, 28(3), pp.603-661.

Turner, P., McLennan, A., Bates, A., and White, M., 2005. *Instant Notes Molecular Biology*. 3rd Ed. Liverpool. Taylor & Francis Group.

Unissa, A.N. and Hanna, L.E., 2017. Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era. *Tuberculosis*, 105, pp.96-107.

van Rensburg, M.J.J., Whitelaw, A.C. and Elisha, B.G., 2012. Genetic basis of rifampicin resistance in methicillin-resistant *Staphylococcus aureus* suggests clonal expansion in hospitals in Cape Town, South Africa. *BMC Microbiology*, 12(1), p.46.

Villar, M., Marimón, J.M., García-Arenzana, J.M., De la Campa, A.G., Ferrándiz, M.J. and Pérez-Trallero, E., 2011. Epidemiological and molecular aspects of rifampicin-resistant *Staphylococcus aureus* isolated from wounds, blood and respiratory samples. *Journal of Antimicrobial Chemotherapy*, 66(5), pp.997-1000.

Wehrli, W., 1983. Rifampin: mechanisms of action and resistance. *Reviews of Infectious Diseases*, 5(Supplement_3), pp. S407-S411.

Wichelhaus, T.A., Schäfer, V., Brade, V. and Böddinghaus, B., 1999. Molecular Characterization of rpoB Mutations Conferring Cross-Resistance to Rifamycins on Methicillin-Resistant *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy*, 43(11), pp.2813-281.